BillionToOne Reports First Quarter 2026 Results and Raises 2026 Revenue Guidance
BillionToOne, Inc. reported its first quarter 2026 financial results, showcasing a significant revenue increase of 84% year-over-year, with total revenue of $108.4 million. The company raised its 2026 revenue forecast to $450 million to $465 million, reflecting ongoing growth in prenatal and oncology testing services. Despite rising operating expenses, the company achieved a net income of $18.0 million, marking a substantial turnaround from a loss in the previous year.
MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) — BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the first quarter ended March 31, 2026 and raised guidance for full year 2026.